Hantz Financial Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hantz Financial Services’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Hold	1	–	–	﹤0.01%	2396
2026 Q1	$1K	Buy	+1	New	+$478	﹤0.01%	2379

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hantz Financial Services's MDGL Position: Q2 2026 in Review

Hantz Financial Services held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 1 share worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

Hantz Financial Services first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Hantz Financial Services held 1 share of Madrigal Pharmaceuticals worth $1K as of Q2 2026.
Hantz Financial Services left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2396 holding.
Hantz Financial Services first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.